Theravance Biopharma Inc (TBPH)
9.17
-0.05
(-0.54%)
USD |
NASDAQ |
Apr 24, 16:00
9.165
0.00 (0.00%)
Pre-Market: 20:00
Theravance Biopharma Shareholders Equity (Quarterly): 213.00M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 213.00M |
| September 30, 2023 | 246.13M |
| June 30, 2023 | 280.16M |
| March 31, 2023 | 370.56M |
| December 31, 2022 | 441.80M |
| September 30, 2022 | 480.58M |
| June 30, 2022 | -349.81M |
| March 31, 2022 | -351.45M |
| December 31, 2021 | -338.57M |
| September 30, 2021 | -323.59M |
| June 30, 2021 | -300.37M |
| March 31, 2021 | -373.22M |
| December 31, 2020 | -303.75M |
| September 30, 2020 | -261.54M |
| June 30, 2020 | -202.34M |
| March 31, 2020 | -157.94M |
| December 31, 2019 | -223.84M |
| September 30, 2019 | -182.80M |
| June 30, 2019 | -137.22M |
| March 31, 2019 | -113.25M |
| December 31, 2018 | -51.59M |
| Date | Value |
|---|---|
| September 30, 2018 | -13.44M |
| June 30, 2018 | 34.39M |
| March 31, 2018 | 63.41M |
| December 31, 2017 | 115.18M |
| September 30, 2017 | 184.12M |
| June 30, 2017 | 241.13M |
| March 31, 2017 | 293.95M |
| December 31, 2016 | 350.23M |
| September 30, 2016 | 297.87M |
| June 30, 2016 | 321.58M |
| March 31, 2016 | 238.54M |
| December 31, 2015 | 243.06M |
| September 30, 2015 | 222.54M |
| June 30, 2015 | 257.67M |
| March 31, 2015 | 289.12M |
| December 31, 2014 | 289.79M |
| September 30, 2014 | 339.82M |
| June 30, 2014 | 384.76M |
| March 31, 2014 | -17.92M |
| December 31, 2013 | -17.04M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-373.22M
Minimum
Mar 2021
480.58M
Maximum
Sep 2022
-77.59M
Average
-202.34M
Median
Jun 2020
Shareholders Equity (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 506.70M |
| Nektar Therapeutics | 130.99M |
| Vanda Pharmaceuticals Inc | 544.91M |
| Fate Therapeutics Inc | 368.42M |
| FibroGen Inc | -204.17M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 382.00M |
| Total Liabilities (Quarterly) | 169.00M |
| Current Ratio | 5.392 |